BioXcel forms oncology subsidiary to free up neuroscience focus

20 April 2022

At the same time as announcing strategic financing agreements worth $260 million, USA-based BioXcel Therapeutics (Nasdaq: BTAI) has revealed the formation of wholly-owned subsidiary OnkosXcel Therapeutics to develop transformative medicines in oncology.

OnkosXcel is focused on the sustained expansion and optimization of the oncology franchise, while providing maximum strategic and financial flexibility, and will progress the development of BXCL701, an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment.

BXCL701 is being evaluated in combination with Merck & Co’s (NYSE: MRK) immuno-oncology blockbuster Keytruda (pembrolizumab) in an ongoing Phase II trial in metastatic castration-resistant prostate cancer patients with either adenocarcinoma or small cell neuroendocrine carcinoma phenotype.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK